Compugen Ltd. shares fall 2.87% intraday as DESTINY-Endometrial01 Phase 3 Trial of ENHERTU begins.

Compugen Ltd. declined 2.87% in intraday trading. The company announced that the first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy (carboplatin and paclitaxel) in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer.